DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Zacks.com on MSN2h
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationDenali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
That's all for our live coverage of the war in Ukraine. We'll be back tomorrow with more updates. Here's a rundown of the key lines from today: Ukraine's military has said it was responsible for a ...
Copyright 2025 The Associated Press. All Rights Reserved. Remote, icy and mostly pristine, Greenland plays an outsized role in the daily weather experienced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback